Comparing Absci (ABSI) & Its Peers

Absci (NASDAQ:ABSIGet Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Absci to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Profitability

This table compares Absci and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Absci -2,633.14% -36.19% -22.99%
Absci Competitors -260.35% -8.17% -2.92%

Valuation & Earnings

This table compares Absci and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Absci $4.78 million -$100.96 million -1.07
Absci Competitors $2.80 billion $101.15 million 13.27

Absci’s rivals have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Absci and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Absci 1 3 3 0 2.29
Absci Competitors 105 765 1304 30 2.57

Absci presently has a consensus target price of $24.00, suggesting a potential upside of 576.06%. As a group, “Commercial physical research” companies have a potential upside of 48.19%. Given Absci’s higher probable upside, research analysts plainly believe Absci is more favorable than its rivals.

Insider & Institutional Ownership

40.0% of Absci shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 11.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Absci rivals beat Absci on 11 of the 12 factors compared.

Absci Company Profile (Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.